Maura K Cosetti

Dr. Maura K Cosetti

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2018 in Otolaryngologic Clinics of North America
Verified
Journal Article
Closed access
VKVivian Kaul
Vivian Kaul
MCMaura K Cosetti
Maura K Cosetti

19 January 2021 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
DVDillan F. Villavisanis
Dillan F. Villavisanis
MMMaria A. Mavrommatis
Maria A. Mavrommatis
EBElisa R. Berson Bs
Elisa R. Berson Bs
CBChristopher P. Bellaire Ba
Christopher P. Bellaire Ba
JRJohn W. Rutland
John W. Rutland
MCMaura K Cosetti
Maura K Cosetti

16 March 2015 in Otolaryngology–Head and Neck Surgery
Verified
Journal Article
Closed access
PDF file
MCMaura K Cosetti
Maura K Cosetti
JGJohn G. Golfinos
John G. Golfinos
JRJr J. Thomas Roland
Jr J. Thomas Roland

6 August 2021 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
AAAnnie E. Arrighi‐Allisan
Annie E. Arrighi‐Allisan
KGKatherine L. Garvey
Katherine L. Garvey
AWAnni Wong
Anni Wong
PFPeter Filip
Peter Filip
JSJanki Shah
Janki Shah
AIAlfred Marc Iloreta
Alfred Marc Iloreta

24 January 2021 in The Laryngoscope
Verified
Journal Article
Open access
PDF file
CLChristine Little
Christine Little
MCMaura K Cosetti
Maura K Cosetti
Objective/Hypothesis: The purpose of this review is to summarize evidence‐based data regarding the ototoxic effects of potential COVID‐19 therapeutics to treat patients suffering from SARS‐CoV‐2.Methods: Medications under investigation as novel therapeutics to treat COVID‐19 were identified using the search term coronavirus therapeutics, COVID therapeutics, and SARS‐CoV‐2 therapeutics on ClinicalTrials.gov and the PubMed Database. A literature review was performed using the PubMed Database for each proposed COVID‐19 therapeutic to identify relevant articles. Search criteria included Medical Subject Headings (MeSH) and key word search terms for ototoxicity, vestibulotoxicity, hearing disorders, and vertigo.Results: Six proposed COVID‐19 therapeutics were identified as possessing ototoxic side effects including chloroquine and hydroxychloroquine, azithromycin, lopinavir‐ritonavir, interferon, ribavirin, and ivermectin.Conclusions: Available evidence suggests that ototoxic effects may be improved or mitigated by stopping the offending agent. Recognition of hearing loss, tinnitus, or imbalance/vertigo is therefore crucial to facilitate early intervention and prevent long‐term damage. Hospitals should consider the inclusion of audiologic monitoring protocols for patients receiving COVID‐19 therapeutics with known ototoxicity, especially in high‐risk patient groups such as the elderly and hearing impaired. Laryngoscope, 131:1626–1632, 2021

1 February 2020 in Otology & Neurotology
Verified
Journal Article
Closed access
KCKevin Chow
Kevin Chow
MCMaura K Cosetti
Maura K Cosetti
Objective: We report a case of recurrent eosinophilic otitis media (EOM) successfully treated with the novel monoclonal IL-5 inhibitor benralizumab. We also review literature relevant to EOM diagnosis and potential for biologic treatment. Patient: A 24-year-old woman with bilateral otitis media with effusion unresponsive to standard treatment. Intervention(s): Multidisciplinary treatment using subcutaneous benralizumab after diagnosis of EOM. Main Outcome Measure(s): Behavioral audiometry, peripheral serology, otomicroscopy, and eosinophilic otitis media symptom severity. Results: Recalcitrant otitis media with effusion (OME) in the setting of nasal polyposis and asthma prompted clinical suspicion for EOM, which was confirmed by pathologic examination of middle ear effusion and soft tissue biopsy. Treatment with benralizumab was initiated by pulmonology and well-tolerated. Within 2 months of treatment onset there was a cessation of EOM symptoms, a reduction of peripheral eosinophil levels, and an improvement in conductive hearing loss. Conclusions: Monoclonal antibodies such as benralizumab may be an effective treatment option for EOM. A high level of clinical suspicion in patients with bronchial asthma, nasal polyposis, and recalcitrant OME may allow early diagnosis of EOM. Awareness of emerging biologic treatment options is important in the management of this challenging entity and may prevent long-term sequelae.